Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

foresiGHt: A Multicenter, Randomized, Parallel-arm, Placebo-controlled (Double- Blind) and Active-controlled (Open-label) Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency

NCT04615273 is registered in ClinicalTrials.gov with Ascendis Pharma Endocrinology Division A/S as lead sponsor.

NCT NCT04615273
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04615273 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
foresiGHt: A Multicenter, Randomized, Parallel-arm, Placebo-controlled (Double- Blind) and Active-controlled (Open-label) Trial to Compare the Efficacy and Safety of Once-weekly Lonapegsomatropin With Placebo and a Daily Somatropin Product in Adults With Growth Hormone Deficiency
Lead sponsor
Ascendis Pharma Endocrinology Division A/S
Phase
Phase 3
Overall status
Completed
Start date
December 3, 2020
Completion date
December 1, 2023
Enrollment
264 (actual)
Sites
113

Conditions

As the registry lists them; a condition with its own page is linked.

endocrine system diseases, growth hormone deficiency, hormone deficiency